uploads///BMY

How Bristol-Myers Squibb’s Key Products Performed in 1Q18

By

Updated

Prioritized brands

Bristol-Myers Squibb’s (BMY) prioritized brands include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, and Empliciti. Total Opdivo sales increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18. The drug registered strong growth in the US market as well as non-US markets. Its US sales increased 23%, from $761 million in 1Q17 to $938 million in 1Q18. Opdivo’s non-US sales increased 57%, from $366 million in 1Q17 to $573 million in 1Q18.

Total Eliquis sales grew 37%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18. Its US sales grew 27%, from $699 million in 1Q17 to $885 million in 1Q18. Non-US sales of Eliquis increased 54%, from $402 million in 1Q17 to $621 million in 1Q18.

Orencia sales registered growth of 11%, rising from $535 million in 1Q17 to $593 million in 1Q18. Its US sales increased 6% from $362 million in 1Q17 to $385 million in 1Q18. Orencia’s non-US sales increased 20%, from $173 million in 1Q17 to $208 million in 1Q18.

Article continues below advertisement

Established brands

Bristol-Myers Squibb’s established brands include Baraclude, Sustiva, Reyataz, and its hepatitis C franchise. That category saw a decline in sales across all major brands. Total sales for Baraclude declined 20%, from $282 million in 1Q17 to $225 million in 1Q18. US sales declined 29%, from $14 million in 1Q17 to $10 million in 1Q18, and non-US sales fell 20%, from $268 million in 1Q17 to $215 million in 1Q18.

Sustiva sales fell a staggering 54%, from $184 million in 1Q17 to $84 million in 1Q18. Total sales from Reyataz fell 36%, from $193 million in 1Q17 to $124 million in 1Q18. Its US sales declined 42%, from $88 million in 1Q17 to $51 million in 1Q18. Non-US sales of Reyataz fell 30%, from $105 million in 1Q17 to $73 million in 1Q18.

In the next part of this series, we’ll take a look at Bristol-Myers Squibb’s financial performance.

Advertisement

More From Market Realist